Skip to Content
You are currently on the new version of our website. Access the old version .
  • Review
  • Open Access

4 April 2020

19 Pages

Potential Molecular Pathways Related to Pulmonary Artery Aneurysm Development: Lessons to Learn from the Aorta

,
,
,
,
,
and
1
Centro de Investigaciones Biomédicas en Red de enfermedades CardioVasculares (CIBERCV), 28029 Madrid, Spain
2
Servicio de Cardiología, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain
3
Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain
4
Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain

Abstract

Pulmonary arterial hypertension (PAH) is a rare disease caused by pulmonary vascular remodeling. Current vasodilator treatments have substantially improved patients’ survival. This improved survival has led to the appearance of complications related to conditions previously underdiagnosed or even ignored, such as pulmonary artery aneurysm (PAA). The presence of a dilated pulmonary artery has been shown to be related to an increased risk of sudden cardiac death among PAH patients. This increased risk could be associated to the development of left main coronary artery compression or pulmonary artery dissection. Nevertheless, very little is currently known about the molecular mechanisms related to PAA. Thoracic aortic aneurysm (TAA) is a well-known condition with an increased risk of sudden death caused by acute aortic dissection. TAA may be secondary to chronic exposure to classic cardiovascular risk factors. In addition, a number of genetic variants have been shown to be related to a marked risk of TAA and dissection as part of multisystemic syndromes or isolated familial TAA. The molecular pathways implied in the development of TAA have been widely studied and described. Many of these molecular pathways are involved in the pathogenesis of PAH and could be involved in PAA. This review aims to describe all these common pathways to open new research lines that could help lead to a better understanding of the pathophysiology of PAH and PAA and their clinical implications.

1. Introduction

Pulmonary artery (PA) dilatation is a common finding among pulmonary arterial hypertension (PAH) patients [1]. Indeed, the detection of a dilated PA often leads to the diagnosis of PAH [2]. Pulmonary artery aneurysm (PAA) is defined as a main PA dilatation above 40 mm diameter [3,4,5] and has been classically diagnosed in post-mortem studies [6]. However, in recent years its detection has increased [3]. This increasing detection is particularly prominent among PAH patients in whom PAA frequency is around 38% and is becoming more common among those patients with long-standing PAH [1]. Some studies relate PAA development to hemodynamic severity among PAH patients [5]. However, this finding is controversial since other published works have shown that a worse hemodynamic profile does not necessarily lead to PAA development [1]. Furthermore, it seems that PA pressure reduction with pulmonary vasodilators is not able to stop PA enlargement in PAH patients [2,7]. PA dilatation is related to an increased risk of sudden cardiac death [8] and among patients with PAA a non-significant higher proportion of sudden cardiac death has been described [1]. This increased risk of sudden cardiac death may be related to the presence of life-threatening complications such as PA dissection [9,10] and left main coronary artery compression [11].
Thoracic aortic aneurysm (TAA) is a well-known condition characterized by a progressive aortic enlargement, which often leads to potentially fatal complications such as aortic dissection [12]. TAA is formally defined as a dilatation of the aorta of at least a 50% in diameter compared with the normal diameter [13,14]. There are several acquired conditions leading to this abnormal growth including classical cardiovascular risk factors, vasculitis, or trauma [15]. In this regard, genetics also plays an important role. Approximately, 20% of TAA patients have a family history of the disease with 25% of them carrying a genetic variant affecting proteins involved in the extracellular matrix (ECM), vascular smooth muscle cells (SMC), or the transforming growth factor β (TGF-β) pathway. Indeed, TAA histology is characterized by the loss of SMC in the vessel media layer and the destruction of the ECM by metalloproteinases [16]. Genetic variants associated with TAA are often genetic determinants of complex syndromes affecting multiple organs and systems [17].
To our knowledge, genetic variants related to PAA have not yet been described. In fact, the identification of mutations classically related to familial PAH (BMPR-2, TBX4, KCNK3) are not more frequent among patients with a PAA [1]. Furthermore, although some molecular pathways altered in PAH have been shown to be somehow implicated in great vessel aneurysm development (e.g., increased ALK1 receptor pathway activation in TAA [18], ENG mutations in some patients with hereditary hemorrhagic telangiectasia [19] and TAA or CAV1 and AQP1 implication in abdominal aorta aneurysm [20,21]), their association with PAA has not been described. However, some of the molecular pathways related to the development of TAA have been described to have a role in PAH pathogenesis [17]. In this review we aim to summarize these common molecular pathways to help researchers identify potential molecular targets that could be involved in the development of PAA among PAH patients.

2. Genetic Variants in Thoracic Aortic Aneurysms

At the time of writing this review, there are 29 identified genes that have been shown to be associated with TAA development. These genes usually encode for components of the ECM, the TGF-ß pathway, or are involved in SMC function [17]. The genes affected in TAA include: ACTA2, BGN, COL1A2, COL3A1, COL5A1, COL5A2, EFFEMP2, ELN, EMILIN1, FBN1, FBN2, FLNA, FOXE3, LOX, MAT2A, MFAP5, MYH11, MYLK, NOTCH1, PRKG1, SKI, SLC2A10, SMAD2, SMAD3, SMAD4, TGFB2, TGFB3, THFBR1, and TGFBR2.
The identification of these mutations is useful not only for family screening but also for prognostic implications derived from a portion of variants and genes with well-established genotype–phenotype correlations [17]. Based on the increased risk for acute aortic syndrome, the diameter threshold, which marks the indication for surgery, can change depending on the molecular etiology [17,22].
The hereditary influence that causes or predisposes a person to systemic artery dilation can be divided among (i) those carrying a highly penetrant variant and frequently showing syndromic features (e.g., FBN and Marfan syndrome, TGF-β and Loeys–Dietz syndromes or collagen and Ehlers–Danlos syndrome (Table 1)); (ii) those with less penetrant and perhaps more frequent variants in whom environmental influence might be key to aneurysm development (e.g., rare variants in MYH11 and ACTA2 associated with familial and sporadic non-syndromic TAA); and (iii) a group of patients not carrying a net hereditary risk charge for aneurysm development who need a heavy environmental influence for aneurysm development (elderly, hypertension, atherosclerosis) [23]. These subdivisions are an adaptation to the threshold theories of genetic risk and might be applicable to PAA development. However, more research is necessary in the field for further conclusions in this regard.
Table 1. Common molecular pathways between thoracic aneurysm and pulmonary hypertension or pulmonary aneurysm. BAV = bicuspid aortic valve; BMP = bone morphogenetic protein; ECM = extracellular matrix; OMIM = online mendelian inheritance in man; PA = pulmonary artery; PAH = pulmonary arterial hypertension; PH = pulmonary hypertension; SMC = smooth muscle cell; TAA = thoracic aortic aneurysm; TGF-β = transforming growth factor β ** PH and PA dilatation in Adams–Oliver syndrome related to pulmonary vein stenosis. ^^ Loss of SMAD3 function promotes vascular remodeling but PH has not been described in patients with pulmonary hypertension.

3. Extracellular Matrix Dysregulation in the Genesis of Pulmonary Vascular Remodeling

In the last few years, the ECM has been shown to play an essential role in the pathogenesis of PAH. Changes in the ECM seem to precede the appearance of pulmonary vascular remodeling. These changes in the ECM include increased collagen deposition or cross-linkage and disruption of the elastic laminae [24]. ECM remodeling is an early phenomenon in the pathogenesis of the disease and it is suspected to be a cause of the pulmonary vascular remodeling instead of a consequence of increased afterload [24]. Thus, increased PA stiffness triggers pulmonary vascular remodeling by activating different signaling pathways [24]. The most common molecular pathways altered in PAH include the bone morphogenetic protein (BMP), TGF-β pathway, abnormal micro-RNA expression, increased growth factors (platelet-derived and vascular endothelial growth factors among others), altered inflammatory pathways (interleukins IL-6, IL-1β), mitochondrial metabolism, other neurohormonal pathways (i.e., serotonin, adrenergic), prostacyclin/cAMP/PKA, endothelin/calcium signaling, and NO/sGC/cGMP/PDE5 all leading to endothelial dysfunction and abnormal SMC proliferation and reduced apoptosis [25].

4. Molecular Pathways Affected in Both Pulmonary Hypertension and Aortic Thoracic Aneurysms

As described before, for both TAA and PAH, histological changes affecting the ECM might participate on the origin of the disease. Some of the genes that have been shown to be related to TAA development encode for proteins, which, in the absence of described mutations, are somehow involved in PAH pathogenesis (Table 1). Genes are classified depending on their potential effects on PAH development: increased ECM stiffness or increased cell proliferation (Figure 1).
Figure 1. Graphical abstract representing genes related to thoracic aortic aneurysms that also encode for proteins implicated in the pathogenesis of pulmonary arterial hypertension (extracellular matrix stiffness (left column), increased cell proliferation (right column)). Syndromes in which pulmonary and aortic aneurysms may be present are also listed.

7. Certain Syndromes May Present Aortic and Pulmonary Artery Aneurysms

In addition to the shared pathways between familial or syndromic TAA and PAH, some of these syndromes are related to the development of PAA in normotensive patients. Genetic variants associated with these syndromes and their clinical features are detailed in Table 1.
Meester–Loeys syndrome: A single case of PAA in a patient with this condition has been described, with concomitant diagnosis of mitral valve prolapse [30].
Ehlers–Danlos syndrome: A single case of a patient with a PAA has been reported among Ehlers–Danlos syndrome patients [34]. Furthermore, the presence of PAA seems to be less frequent among connective tissue disease-related PAH patients [1].
Cutis laxa, AR type I: This ECM alteration is responsible for a syndrome with different clinical features including PAA [31,36].
Marfan syndrome: The dilatation of the pulmonary artery was a minor cardiovascular criteria for Marfan Syndrome diagnosis until the definition of the revised Ghent nosology, where it was not included [38,71]. However, up to a 74% of patients with Marfan Syndrome present a PA dilatation [72] and 15% a PAA [73], including PAA and PA dissection, which confirms that histological changes also affect the pulmonary vasculature [39,40].
FLNA mutations: As previously stated, only two cases of familial PAH with PAA have been described in the literature [44]. However, the presence of PAA among patients with filamin cardiac variants is not common.
Shprintzen–Goldberg syndrome: A single case of PAA has been reported among patients with mutations in the Sloan–Kettering proto-oncogene [53].
Loeys–Dietz syndrome: The diagnosis of PAA among Loeys–Dietz syndrome patients is not as common as it is for the Marfan syndrome patients, being limited to a single reported case [58,60]. However, in some patients, a concomitant diagnosis of TAA and PAA has been described with similar histological changes described in both arteries [74].

8. Hemodynamic Overload Contributes to Development of Both Aortic and Pulmonary Aneurysms

Hypertension and PAH are common causes for the development of TAA and PAA, respectively. However, not every patient exposed to an increased intravascular pressure develops a great vessel aneurysm. Furthermore, the effect of antihypertensive drugs or pulmonary vasodilators on artery diameter change is debatable [2,7]. Thus, besides increased intravascular pressure, patients who finally develop abnormal artery growth must present a genetic susceptibility triggering ECM changes responsible of aneurysm development.
Hypertension is a well-known risk factor for aortic root enlargement and TAA [75]. Cystic medial degeneration or necrosis are the typical histological findings in patients with TAA and dissection and its appearance is accelerated by aging and hypertension [76]. Moreover, a long exposure to hypertension seems to play an important role in TAA development since the prevalence among untreated patients with recent diagnosis is low [77]. Contradictory results about the influence of high blood pressure in the development of TAA have been described [78]. Nevertheless, cumulative evidence seem to support the fact that the aortic root dilatation is hypertensive-related organ damage related to a worse prognosis among patients with high blood pressure [78]. Antihypertensive drugs are commonly used to slow the aortic root enlargement among Marfan syndrome patients. Propranolol, a non-selective beta-blocker, has been shown to reduce aortic root growth and clinical events in this population [79]. Treatment with the angiotensin-II receptor blocker losartan was shown to be effective in stopping the progressive enlargement of the aortic root in preclinical mice models of Marfan syndrome [80]. However, controversial results have been obtained in different clinical trials, with no differences in effectiveness when compared to betablockers [81,82,83,84]. Whether antihypertensive drugs are effective in the reduction of aortic dilatation among the hypertensive population is still debatable [78]. However, based in the evidence obtained in clinical trials with Marfan syndrome patients, current guidelines recommend the use of betablockers as the preferred drug in hypertensive patients with aortic enlargement [85].
Physiopathological data about PAA development is scarce. PAA appears as a consequence of different diseases [86], being more common among patients with PAH especially among those with congenital heart defects [1]. In PAH, histological damage is not confined to lung capillaries. Structural changes affecting the ECM on the PA wall, with increased collagen content and an increased elastolytic activity, leads to an increased PA stiffness that affects the ventricular–arterial coupling and could be responsible of the PAA development [87]. However, despite PAA being common among PAH patients, hemodynamic severity of PAH has not shown to be an independent risk factor for PAA development in this population [1]. Furthermore, effective PA pressure reduction with pulmonary vasodilators have failed to stop progressive PA enlargement [2,7]. Thus, it seems that a chronic exposure to an increased afterload worsen irreversible ECM changes leading to PA growth [1]. Whether there is a genetic predisposition for these changes, and whether the molecular pathways affected in these patients are the same as those affected in TAA patients is still unexplored.

9. Diameter-Based Indication for Prophylactic Surgery: Do We Need a Variant-Dependent Approach for PAA?

In addition to losartan and beta-blockers, there are no available treatments to stop TAA enlargement and to reduce the incidence of fatal complications, especially aortic dissection. For this reason, current management is based on the identification of patients at a higher risk for complications to perform a prophylactic resection surgery [22]. The indication for this type of surgery is based both on the presence of an identified mutation and on aortic diameter or fast growth [17,22]. However, the suitability of these recommendations is widely discussed as the diameter of TAA in patients with acute dissection is lower than 55 mm in the majority of the cases and lower than 50 mm in 40% of the cases [88]. Thus, the indication of early surgery should be based on the identification of high-risk patients depending on the presence of specific mutations, the diagnosis of certain syndromes, or family history of aortic dissection.
The indication for resection surgery becomes even more difficult when talking about PAA. In this setting, the lack of strong evidence is added to the high surgical risk for PAH with up to a 25% mortality risk for cardiac surgery [89]. The risk of sudden cardiac death among PAH patients reaches 30% [90]. Although an increased PA diameter has been shown to be an independent risk factor for sudden cardiac death in PAH patients [8], there are no necropsy registries allowing for the confirmation of PA dissection being the main cause of sudden death in this population. Furthermore, there are some case series of patients with confirmed PA dissection in whom a conservative strategy was chosen with an acceptable long-term survival and who presented with some PA branches dissection without a severely dilated main PA [9,10]. Furthermore, there are other conditions that could be responsible of an unexpected death in PAH patients, such as left main coronary artery compression by a PAA, which could induce myocardial ischemia and fatal ventricular arrhythmias [11]. Some authors have proposed recommendations for prophylactic surgery in patients with a PAA, which include a diameter threshold of 55 mm or even the diagnosis of PAH [3,4]. However, in Marfan syndrome patients, the indication for elective surgery over the PA is uncommon and reserved for those patients with a PA diameter larger than 60 mm, as few complications related to PA enlargement have been described in these patients [72]. Furthermore, left main coronary artery compression, which could explain an important proportion of sudden deaths in patients with a PAA, can be properly treated with percutaneous procedures, avoiding the extremely high surgical risk [11]. Thus, the evidence available does not support a recommendation for early surgery in PAH patients based on the PA diameter. The identification of mutations related to a higher risk of PAA and its complications could be helpful in the decision-making process in PAH patients with a PAA. Tissue and molecular evaluation of the PA of patients undergoing lung transplant or autopsy studies is essential to improve our knowledge.

11. Conclusions

Current knowledge regarding PAA pathogenesis is scarce. TAA and PAH share molecular pathways responsible of changes in the ECM and vascular remodeling in both systemic and pulmonary circulation. The study of these common pathways might help to better understand the pathophysiology of PAH and its consequences, including PAA and its complications. Furthermore, it could help to identify novel molecular targets beyond pulmonary vasodilator therapies that would open new therapeutic avenues in the field.

Funding

J.N. is a recipient of a predoctoral grant (Jordi Soler Soler) through CIBERCV. E.O. is a recipient of funds from Programa de Atracción de Talento (2017-T1/BMD-5185) of Comunidad de Madrid. P.E. is a recipient of a grant of the Spanish Ministry of Science and Universities for the study of molecular bases in pulmonary arterial hypertension (PI 18/01233). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación, and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505).

Acknowledgments

We would like to thank Carlos Galan-Arriola for his contribution to this work by designing and drawing the graphical abstract.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

BMP/BMPRbone morphogenetic protein/BMP receptor
ECMextracellular matrix
PApulmonary artery
PAHpulmonary arterial hypertension
PAApulmonary artery aneurysm
SMCsmooth muscle cells
TAAthoracic aortic aneurysm
TGF-βtransforming growth factor-β

References

  1. Nuche, J.; Montero Cabezas, J.M.; Jiménez López-Guarch, C.; Velázquez Martín, M.; Alonso Charterina, S.; Revilla Ostolaza, Y.; Arribas Ynsaurriaga, F.; Escribano Subías, P. Frequency, Predictors, and Prognostic Impact of Pulmonary Artery Aneurysms in Patients With Pulmonary Arterial Hypertension. Am. J. Cardiol. 2019, 123, 474–481. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  2. Boerrigter, B.; Mauritz, G.J.; Marcus, J.T.; Helderman, F.; Postmus, P.E.; Westerhof, N.; Vonk-Noordegraaf, A. Progressive dilatation of the main pulmonary artery is a characteristic of pulmonary arterial hypertension and is not related to changes in pressure. Chest 2010, 138, 1395–1401. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  3. Duijnhouwer, A.L.; Navarese, E.P.; Van Dijk, A.P.; Loeys, B.; Roos-Hesselink, J.W.; De Boer, M.J. Aneurysm of the Pulmonary Artery, a Systematic Review and Critical Analysis of Current Literature. Congenit. Heart Dis. 2016, 11, 102–109. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  4. Kreibich, M.; Siepe, M.; Kroll, J.; Höhn, R.; Grohmann, J.; Beyersdorf, F. Aneurysms of the pulmonary artery. Circulation 2015, 131, 310–316. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  5. Sakata, K.; Satoh, T.; Isaka, A.; Uesugi, Y.; Furuya, M.; Matsushita, K.; Yoshino, H. Cardiac dysfunction of pulmonary artery aneurysm in patients with pulmonary arterial hypertension. Int. J. Cardiol. 2017, 228, 1035–1040. [Google Scholar] [CrossRef] [Scilit]
  6. Deterling, R.A., Jr.; Clagett, O.T. Aneurysm of the pulmonary artery; review of the literature and report of a case. Am. Heart J. 1947, 34, 471–499. [Google Scholar] [CrossRef] [Scilit]
  7. Akagi, S.; Nakamura, K.; Sarashina, T.; Ejiri, K.; Kasahara, S.; Ito, H. Progression of pulmonary artery dilatation in patients with pulmonary hypertension coexisting with a pulmonary artery aneurysm. J. Cardiol. 2018, 71, 517–522. [Google Scholar] [CrossRef] [Scilit]
  8. Żyłkowska, J.; Kurzyna, M.; Florczyk, M.; Burakowska, B.; Grzegorczyk, F.; Burakowski, J.; Wieteska, M.; Oniszh, K.; Biederman, A.; Wawrzyńska, L.; et al. Pulmonary artery dilatation correlates with the risk of unexpected death in chronic arterial or thromboembolic pulmonary hypertension. Chest 2012, 142, 1406–1416. [Google Scholar] [CrossRef] [Scilit]
  9. Nuche, J.; Montero Cabezas, J.M.; Alonso Charterina, S.; Escribano Subías, P. Management of incidentally diagnosed pulmonary artery dissection in patients with pulmonary arterial hypertension. Eur. J. Cardiothorac. Surg. 2019, 56, 210–212. [Google Scholar] [CrossRef] [Scilit]
  10. Florczyk, M.; Wieteska, M.; Kurzyna, M.; Gościniak, P.; Pepke-Żaba, J.; Biederman, A.; Torbicki, A. Acute and chronic dissection of pulmonary artery: New challenges in pulmonary arterial hypertension? Pulm. Circ. 2018, 8, 2045893217749114. [Google Scholar] [CrossRef] [Scilit]
  11. Galiè, N.; Saia, F.; Palazzini, M.; Manes, A.; Russo, V.; Bacchi Reggiani, M.L.; Dall’Ara, G.; Monti, E.; Dardi, F.; Albini, A.; et al. Left Main Coronary Artery Compression in Patients With Pulmonary Arterial Hypertension and Angina. J. Am. Coll. Cardiol. 2017, 69, 2808–2817. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  12. Kim, J.B.; Spotnitz, M.; Lindsay, M.E.; MacGillivray, T.E.; Isselbacher, E.M.; Sundt, T.M. Risk of Aortic Dissection in the Moderately Dilated Ascending Aorta. J. Am. Coll. Cardiol. 2016, 68, 1209–1219. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  13. Creager, M.A.; Belkin, M.; Bluth, E.I.; Casey, D.E.; Chaturvedi, S.; Dake, M.D.; Fleg, J.L.; Hirsch, A.T.; Jaff, M.R.; Kern, J.A.; et al. 2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS Key data elements and definitions for peripheral atherosclerotic vascular disease: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to develop Clinical Data Standards for peripheral atherosclerotic vascular disease). J. Am. Coll. Cardiol. 2012, 59, 294–357. [Google Scholar] [CrossRef] [Scilit]
  14. Goldstein, S.A.; Evangelista, A.; Abbara, S.; Arai, A.; Asch, F.M.; Badano, L.P.; Bolen, M.A.; Connolly, H.M.; Cuéllar-Calàbria, H.; Czerny, M.; et al. Multimodality imaging of diseases of the thoracic aorta in adults: From the American Society of Echocardiography and the European Association of Cardiovascular Imaging: Endorsed by the Society of Cardiovascular Computed Tomography and Society for Cardiovascular Magnetic Resonance. J. Am. Soc. Echocardiogr. 2015, 28, 119–182. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  15. Ferro, C.R.; de Oliveira, D.C.; Guerra, F.e.F.; de Lucena, A.J.; Nunes, F.P.; Ortiz, S.T.; Egito, E.S.; de Sousa, L.C.; Jatene, A.D.; Piegas, L.S. Prevalence and risk factors for combined coronary artery disease and aortic aneurysm. Arq. Bras. Cardiol. 2007, 88, 40–44. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  16. Rabkin, S.W. The Role Matrix Metalloproteinases in the Production of Aortic Aneurysm. Prog. Mol. Biol. Transl. Sci. 2017, 147, 239–265. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  17. Brownstein, A.J.; Kostiuk, V.; Ziganshin, B.A.; Zafar, M.A.; Kuivaniemi, H.; Body, S.C.; Bale, A.E.; Elefteriades, J.A. Genes Associated with Thoracic Aortic Aneurysm and Dissection: 2018 Update and Clinical Implications. Aorta (Stamford) 2018, 6, 13–20. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  18. Jones, J.A.; Barbour, J.R.; Stroud, R.E.; Bouges, S.; Stephens, S.L.; Spinale, F.G.; Ikonomidis, J.S. Altered transforming growth factor-beta signaling in a murine model of thoracic aortic aneurysm. J. Vasc Res. 2008, 45, 457–468. [Google Scholar] [CrossRef] [Scilit]
  19. Gillis, E.; Van Laer, L.; Loeys, B.L. Genetics of thoracic aortic aneurysm: At the crossroad of transforming growth factor-β signaling and vascular smooth muscle cell contractility. Circ. Res. 2013, 113, 327–340. [Google Scholar] [CrossRef] [Scilit]
  20. Takayanagi, T.; Crawford, K.J.; Kobayashi, T.; Obama, T.; Tsuji, T.; Elliott, K.J.; Hashimoto, T.; Rizzo, V.; Eguchi, S. Caveolin 1 is critical for abdominal aortic aneurysm formation induced by angiotensin II and inhibition of lysyl oxidase. Clin. Sci. (Lond) 2014, 126, 785–794. [Google Scholar] [CrossRef] [Scilit]
  21. Wintmo, P.; Johansen, S.H.; Hansen, P.B.L.; Lindholt, J.S.; Urbonavicius, S.; Rasmussen, L.M.; Bie, P.; Jensen, B.L.; Stubbe, J. The water channel AQP1 is expressed in human atherosclerotic vascular lesions and AQP1 deficiency augments angiotensin II-induced atherosclerosis in mice. Acta Physiol. 2017, 220, 446–460. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  22. Erbel, R.; Aboyans, V.; Boileau, C.; Bossone, E.; Bartolomeo, R.D.; Eggebrecht, H.; Evangelista, A.; Falk, V.; Frank, H.; Gaemperli, O.; et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur. Heart J. 2014, 35, 2873–2926. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  23. Pinard, A.; Jones, G.T.; Milewicz, D.M. Genetics of Thoracic and Abdominal Aortic Diseases. Circ. Res. 2019, 124, 588–606. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  24. Thenappan, T.; Chan, S.Y.; Weir, E.K. Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension. Am. J. Physiol Heart Circ. Physiol. 2018, 315, H1322–H1331. [Google Scholar] [CrossRef] [Scilit]
  25. Thompson, A.A.R.; Lawrie, A. Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension. Trends Mol. Med. 2017, 23, 31–45. [Google Scholar] [CrossRef] [Scilit]
  26. Milewicz, D.M.; Østergaard, J.R.; Ala-Kokko, L.M.; Khan, N.; Grange, D.K.; Mendoza-Londono, R.; Bradley, T.J.; Olney, A.H.; Adès, L.; Maher, J.F.; et al. De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunction. Am. J. Med. Genet. A 2010, 152A, 2437–2443. [Google Scholar] [CrossRef] [Scilit]
  27. Guo, D.C.; Pannu, H.; Tran-Fadulu, V.; Papke, C.L.; Yu, R.K.; Avidan, N.; Bourgeois, S.; Estrera, A.L.; Safi, H.J.; Sparks, E.; et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat. Genet. 2007, 39, 1488–1493. [Google Scholar] [CrossRef] [Scilit]
  28. Roder, C.; Peters, V.; Kasuya, H.; Nishizawa, T.; Wakita, S.; Berg, D.; Schulte, C.; Khan, N.; Tatagiba, M.; Krischek, B. Analysis of ACTA2 in European Moyamoya disease patients. Eur. J. Paediatr. Neurol. 2011, 15, 117–122. [Google Scholar] [CrossRef] [Scilit]
  29. Regalado, E.S.; Mellor-Crummey, L.; De Backer, J.; Braverman, A.C.; Ades, L.; Benedict, S.; Bradley, T.J.; Brickner, M.E.; Chatfield, K.C.; Child, A.; et al. Clinical history and management recommendations of the smooth muscle dysfunction syndrome due to ACTA2 arginine 179 alterations. Genet. Med. 2018, 20, 1206–1215. [Google Scholar] [CrossRef] [Scilit]
  30. Meester, J.A.; Vandeweyer, G.; Pintelon, I.; Lammens, M.; Van Hoorick, L.; De Belder, S.; Waitzman, K.; Young, L.; Markham, L.W.; Vogt, J.; et al. Loss-of-function mutations in the X-linked biglycan gene cause a severe syndromic form of thoracic aortic aneurysms and dissections. Genet. Med. 2017, 19, 386–395. [Google Scholar] [CrossRef] [Scilit]
  31. Dasouki, M.; Markova, D.; Garola, R.; Sasaki, T.; Charbonneau, N.L.; Sakai, L.Y.; Chu, M.L. Compound heterozygous mutations in fibulin-4 causing neonatal lethal pulmonary artery occlusion, aortic aneurysm, arachnodactyly, and mild cutis laxa. Am. J. Med. Genet. A 2007, 143A, 2635–2641. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  32. Mochida, Y.; Parisuthiman, D.; Yamauchi, M. Biglycan is a positive modulator of BMP-2 induced osteoblast differentiation. Adv. Exp. Med. Biol. 2006, 585, 101–113. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  33. Leistritz, D.F.; Pepin, M.G.; Schwarze, U.; Byers, P.H. COL3A1 haploinsufficiency results in a variety of Ehlers-Danlos syndrome type IV with delayed onset of complications and longer life expectancy. Genet. Med. 2011, 13, 717–722. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  34. Zamora Muciño, A.; Gómez Jaume, A.; Gorodezky, M.; Pérez Padilla, R.; Amigo, M.C.; Barrios, R. [Cardiovascular abnormalities in Ehlers-Danlos syndrome. Report of a case]. Arch. Inst. Cardiol. Mex. 1989, 59, 301–307. [Google Scholar] [PubMed]
  35. Hoyer, J.; Kraus, C.; Hammersen, G.; Geppert, J.P.; Rauch, A. Lethal cutis laxa with contractural arachnodactyly, overgrowth and soft tissue bleeding due to a novel homozygous fibulin-4 gene mutation. Clin. Genet. 2009, 76, 276–281. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  36. Adès, L.C.; Knight, W.B.; Byard, R.W.; Bateman, J.F.; Esquivel, J.A.; Mee, R.B.; Haan, E.A.; Milewicz, D.M. Clinicopathologic findings in congenital aneurysms of the great vessels. Am. J. Med. Genet. 1996, 66, 289–299. [Google Scholar] [CrossRef]
  37. Merklinger, S.L.; Wagner, R.A.; Spiekerkoetter, E.; Hinek, A.; Knutsen, R.H.; Kabir, M.G.; Desai, K.; Hacker, S.; Wang, L.; Cann, G.M.; et al. Increased fibulin-5 and elastin in S100A4/Mts1 mice with pulmonary hypertension. Circ. Res. 2005, 97, 596–604. [Google Scholar] [CrossRef] [Scilit]
  38. Loeys, B.L.; Dietz, H.C.; Braverman, A.C.; Callewaert, B.L.; De Backer, J.; Devereux, R.B.; Hilhorst-Hofstee, Y.; Jondeau, G.; Faivre, L.; Milewicz, D.M.; et al. The revised Ghent nosology for the Marfan syndrome. J. Med. Genet. 2010, 47, 476–485. [Google Scholar] [CrossRef] [Scilit]
  39. Espinola-Zavaleta, N.; Criales-Vera, S.; Herrera, V.; Soto-Abraham, V.; Soto, M.E. Multi-imaging assessment of successful surgical treatment of pulmonary artery dilatation and dissection in Marfan syndrome. Eur. Heart J. Cardiovasc. Imaging 2017, 18, 607. [Google Scholar] [CrossRef] [Scilit]
  40. Chiu, P.; Irons, M.; van de Rijn, M.; Liang, D.H.; Miller, D.C. Giant Pulmonary Artery Aneurysm in a Patient With Marfan Syndrome and Pulmonary Hypertension. Circulation 2016, 133, 1218–1221. [Google Scholar] [CrossRef] [Scilit]
  41. Loeys, B.L.; Schwarze, U.; Holm, T.; Callewaert, B.L.; Thomas, G.H.; Pannu, H.; De Backer, J.F.; Oswald, G.L.; Symoens, S.; Manouvrier, S.; et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N. Engl. J. Med. 2006, 355, 788–798. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  42. Reinstein, E.; Frentz, S.; Morgan, T.; García-Miñaúr, S.; Leventer, R.J.; McGillivray, G.; Pariani, M.; van der Steen, A.; Pope, M.; Holder-Espinasse, M.; et al. Vascular and connective tissue anomalies associated with X-linked periventricular heterotopia due to mutations in Filamin A. Eur. J. Hum. Genet. 2013, 21, 494–502. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  43. Kyndt, F.; Gueffet, J.P.; Probst, V.; Jaafar, P.; Legendre, A.; Le Bouffant, F.; Toquet, C.; Roy, E.; McGregor, L.; Lynch, S.A.; et al. Mutations in the gene encoding filamin A as a cause for familial cardiac valvular dystrophy. Circulation 2007, 115, 40–49. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  44. Hirashiki, A.; Adachi, S.; Nakano, Y.; Kamimura, Y.; Ogo, T.; Nakanishi, N.; Morisaki, T.; Morisaki, H.; Shimizu, A.; Toba, K.; et al. Left main coronary artery compression by a dilated main pulmonary artery and left coronary sinus of Valsalva aneurysm in a patient with heritable pulmonary arterial hypertension and FLNA mutation. Pulm. Circ. 2017, 7, 734–740. [Google Scholar] [CrossRef] [Scilit]
  45. Lee, V.S.; Halabi, C.M.; Hoffman, E.P.; Carmichael, N.; Leshchiner, I.; Lian, C.G.; Bierhals, A.J.; Vuzman, D.; Mecham, R.P.; Frank, N.Y.; et al. Loss of function mutation in LOX causes thoracic aortic aneurysm and dissection in humans. Proc. Natl. Acad. Sci. USA 2016, 113, 8759–8764. [Google Scholar] [CrossRef] [Scilit]
  46. Nave, A.H.; Mižíková, I.; Niess, G.; Steenbock, H.; Reichenberger, F.; Talavera, M.L.; Veit, F.; Herold, S.; Mayer, K.; Vadász, I.; et al. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 1446–1458. [Google Scholar] [CrossRef] [Scilit]
  47. Martínez-Revelles, S.; García-Redondo, A.B.; Avendaño, M.S.; Varona, S.; Palao, T.; Orriols, M.; Roque, F.R.; Fortuño, A.; Touyz, R.M.; Martínez-González, J.; et al. Lysyl Oxidase Induces Vascular Oxidative Stress and Contributes to Arterial Stiffness and Abnormal Elastin Structure in Hypertension: Role of p38MAPK. Antioxid Redox Signal. 2017, 27, 379–397. [Google Scholar] [CrossRef] [Scilit]
  48. Garg, V.; Muth, A.N.; Ransom, J.F.; Schluterman, M.K.; Barnes, R.; King, I.N.; Grossfeld, P.D.; Srivastava, D. Mutations in NOTCH1 cause aortic valve disease. Nature 2005, 437, 270–274. [Google Scholar] [CrossRef] [Scilit]
  49. Pileggi, S.; De Chiara, B.; Magnoli, M.; Franzosi, M.G.; Merlanti, B.; Bianchini, F.; Moreo, A.; Romeo, G.; Russo, C.F.; Rizzo, S.; et al. Sequencing of NOTCH1 gene in an Italian population with bicuspid aortic valve: Preliminary results from the GISSI OUTLIERS VAR study. Gene 2019, 715, 143970. [Google Scholar] [CrossRef] [Scilit]
  50. Adam, M.P.; Ardinger, H.H.; Pagon, R.A.; Wallace, S.E.; Bean, L.J.H.; Stephens, K.; Amemiya, A. GeneReviews; University of Washington: Seattle, WA, USA, 1993; NBK355754. [Google Scholar]
  51. Patel, M.S.; Taylor, G.P.; Bharya, S.; Al-Sanna’a, N.; Adatia, I.; Chitayat, D.; Suzanne Lewis, M.E.; Human, D.G. Abnormal pericyte recruitment as a cause for pulmonary hypertension in Adams-Oliver syndrome. Am. J. Med. Genet. A 2004, 129A, 294–299. [Google Scholar] [CrossRef] [Scilit]
  52. Dabral, S.; Tian, X.; Kojonazarov, B.; Savai, R.; Ghofrani, H.A.; Weissmann, N.; Florio, M.; Sun, J.; Jonigk, D.; Maegel, L.; et al. Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension. Eur. Respir. J. 2016, 48, 1137–1149. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  53. Carmignac, V.; Thevenon, J.; Adès, L.; Callewaert, B.; Julia, S.; Thauvin-Robinet, C.; Gueneau, L.; Courcet, J.B.; Lopez, E.; Holman, K.; et al. In-frame mutations in exon 1 of SKI cause dominant Shprintzen-Goldberg syndrome. Am. J. Hum. Genet. 2012, 91, 950–957. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  54. Doyle, A.J.; Doyle, J.J.; Bessling, S.L.; Maragh, S.; Lindsay, M.E.; Schepers, D.; Gillis, E.; Mortier, G.; Homfray, T.; Sauls, K.; et al. Mutations in the TGF-β repressor SKI cause Shprintzen-Goldberg syndrome with aortic aneurysm. Nat. Genet. 2012, 44, 1249–1254. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  55. Regalado, E.S.; Guo, D.C.; Villamizar, C.; Avidan, N.; Gilchrist, D.; McGillivray, B.; Clarke, L.; Bernier, F.; Santos-Cortez, R.L.; Leal, S.M.; et al. Exome sequencing identifies SMAD3 mutations as a cause of familial thoracic aortic aneurysm and dissection with intracranial and other arterial aneurysms. Circ. Res. 2011, 109, 680–686. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  56. Zabini, D.; Granton, E.; Hu, Y.; Miranda, M.Z.; Weichelt, U.; Breuils Bonnet, S.; Bonnet, S.; Morrell, N.W.; Connelly, K.A.; Provencher, S.; et al. Loss of SMAD3 Promotes Vascular Remodeling in Pulmonary Arterial Hypertension via MRTF Disinhibition. Am. J. Respir. Crit. Care Med. 2018, 197, 244–260. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  57. MacCarrick, G.; Black, J.H.; Bowdin, S.; El-Hamamsy, I.; Frischmeyer-Guerrerio, P.A.; Guerrerio, A.L.; Sponseller, P.D.; Loeys, B.; Dietz, H.C. Loeys-Dietz syndrome: A primer for diagnosis and management. Genet. Med. 2014, 16, 576–587. [Google Scholar] [CrossRef] [Scilit]
  58. Muramatsu, Y.; Kosho, T.; Magota, M.; Yokotsuka, T.; Ito, M.; Yasuda, A.; Kito, O.; Suzuki, C.; Nagata, Y.; Kawai, S.; et al. Progressive aortic root and pulmonary artery aneurysms in a neonate with Loeys-Dietz syndrome type 1B. Am. J. Med. Genet. A 2010, 152A, 417–421. [Google Scholar] [CrossRef] [Scilit]
  59. Goumans, M.J.; Ten Dijke, P. TGF-β Signaling in Control of Cardiovascular Function. Cold Spring Harb Perspect. Biol. 2018, 10. [Google Scholar] [CrossRef] [Scilit]
  60. Kuppler, K.M.; Kirse, D.J.; Thompson, J.T.; Haldeman-Englert, C.R. Loeys-Dietz syndrome presenting as respiratory distress due to pulmonary artery dilation. Am. J. Med. Genet. A 2012, 158A, 1212–1215. [Google Scholar] [CrossRef] [Scilit]
  61. Ghali, N.; Sobey, G.; Burrows, N. Ehlers-Danlos syndromes. BMJ 2019, 366, l4966. [Google Scholar] [CrossRef] [Scilit]
  62. Malfait, F.; De Paepe, A. The Ehlers-Danlos syndrome. Adv. Exp. Med. Biol. 2014, 802, 129–143. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  63. Mannucci, L.; Luciano, S.; Salehi, L.B.; Gigante, L.; Conte, C.; Longo, G.; Ferradini, V.; Piumelli, N.; Brancati, F.; Ruvolo, G.; et al. Mutation analysis of the FBN1 gene in a cohort of patients with Marfan Syndrome: A 10-year single center experience. Clin. Chim. Acta. 2019. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  64. Xia, X.D.; Lee, J.; Khan, S.; Ye, L.; Li, Y.; Dong, L. Suppression of Phosphatidylinositol 3-Kinase/Akt Signaling Attenuates Hypoxia-Induced Pulmonary Hypertension Through the Downregulation of Lysyl Oxidase. DNA Cell Biol. 2016, 35, 599–606. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  65. Lindsay, M.E.; Schepers, D.; Bolar, N.A.; Doyle, J.J.; Gallo, E.; Fert-Bober, J.; Kempers, M.J.; Fishman, E.K.; Chen, Y.; Myers, L.; et al. Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat. Genet. 2012, 44, 922–927. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  66. Bertoli-Avella, A.M.; Gillis, E.; Morisaki, H.; Verhagen, J.M.A.; de Graaf, B.M.; van de Beek, G.; Gallo, E.; Kruithof, B.P.T.; Venselaar, H.; Myers, L.A.; et al. Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections. J. Am. Coll. Cardiol. 2015, 65, 1324–1336. [Google Scholar] [CrossRef] [Scilit]
  67. Nastase, M.V.; Young, M.F.; Schaefer, L. Biglycan: A multivalent proteoglycan providing structure and signals. J. Histochem. Cytochem. 2012, 60, 963–975. [Google Scholar] [CrossRef] [Scilit]
  68. Sasaki, E.; Byrne, A.T.; Phelan, E.; Cox, D.W.; Reardon, W. A review of filamin A mutations and associated interstitial lung disease. Eur. J. Pediatr. 2019, 178, 121–129. [Google Scholar] [CrossRef] [Scilit]
  69. Rol, N.; Kurakula, K.B.; Happé, C.; Bogaard, H.J.; Goumans, M.J. TGF-β and BMPR2 Signaling in PAH: Two Black Sheep in One Family. Int. J. Mol. Sci. 2018, 19. [Google Scholar] [CrossRef] [Scilit]
  70. Hu, H.H.; Chen, D.Q.; Wang, Y.N.; Feng, Y.L.; Cao, G.; Vaziri, N.D.; Zhao, Y.Y. New insights into TGF-β/Smad signaling in tissue fibrosis. Chem. Biol. Interact. 2018, 292, 76–83. [Google Scholar] [CrossRef] [Scilit]
  71. De Paepe, A.; Devereux, R.B.; Dietz, H.C.; Hennekam, R.C.; Pyeritz, R.E. Revised diagnostic criteria for the Marfan syndrome. Am. J. Med. Genet. 1996, 62, 417–426. [Google Scholar] [CrossRef]
  72. von Kodolitsch, Y.; Demolder, A.; Girdauskas, E.; Kaemmerer, H.; Kornhuber, K.; Muino Mosquera, L.; Morris, S.; Neptune, E.; Pyeritz, R.; Rand-Hendriksen, S.; et al. Features of Marfan syndrome not listed in the Ghent nosology—The Dark Side of the Disease. Expert Rev. Cardiovasc. Ther. 2019. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  73. Sheikhzadeh, S.; De Backer, J.; Gorgan, N.R.; Rybczynski, M.; Hillebrand, M.; Schüler, H.; Bernhardt, A.M.; Koschyk, D.; Bannas, P.; Keyser, B.; et al. The main pulmonary artery in adults: A controlled multicenter study with assessment of echocardiographic reference values, and the frequency of dilatation and aneurysm in Marfan syndrome. Orphanet. J. Rare Dis. 2014, 9, 203. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  74. Rizzo, S.; Stellin, G.; Milanesi, O.; Padalino, M.; Vricella, L.A.; Thiene, G.; Cameron, D.E.; Basso, C.; Vida, V.L. Aortic and Pulmonary Root Aneurysms in a Child With Loeys-Dietz Syndrome. Ann. Thorac. Surg. 2016, 101, 1193–1195. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  75. Isselbacher, E.M. Thoracic and abdominal aortic aneurysms. Circulation 2005, 111, 816–828. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  76. Carlson, R.G.; Lillehei, C.W.; Edwards, J.E. Cystic medial necrosis of the ascending aorta in relation to age and hypertension. Am. J. Cardiol. 1970, 25, 411–415. [Google Scholar] [CrossRef] [Scilit]
  77. Cuspidi, C.; Meani, S.; Valerio, C.; Esposito, A.; Sala, C.; Maisaidi, M.; Zanchetti, A.; Mancia, G. Ambulatory blood pressure, target organ damage and aortic root size in never-treated essential hypertensive patients. J. Hum. Hypertens 2007, 21, 531–538. [Google Scholar] [CrossRef] [Scilit]
  78. Mulè, G.; Nardi, E.; Morreale, M.; Castiglia, A.; Geraci, G.; Altieri, D.; Cacciatore, V.; Schillaci, M.; Vaccaro, F.; Cottone, S. The Relationship Between Aortic Root Size and Hypertension: An Unsolved Conundrum. Adv. Exp. Med. Biol. 2017, 956, 427–445. [Google Scholar] [CrossRef] [Scilit]
  79. Shores, J.; Berger, K.R.; Murphy, E.A.; Pyeritz, R.E. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan’s syndrome. N. Engl. J. Med. 1994, 330, 1335–1341. [Google Scholar] [CrossRef] [Scilit]
  80. Habashi, J.P.; Doyle, J.J.; Holm, T.M.; Aziz, H.; Schoenhoff, F.; Bedja, D.; Chen, Y.; Modiri, A.N.; Judge, D.P.; Dietz, H.C. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 2011, 332, 361–365. [Google Scholar] [CrossRef] [Scilit]
  81. Elbadawi, A.; Omer, M.A.; Elgendy, I.Y.; Abuzaid, A.; Mohamed, A.H.; Rai, D.; Saad, M.; Mentias, A.; Rezq, A.; Kamal, D.; et al. Losartan for Preventing Aortic Root Dilatation in Patients with Marfan Syndrome: A Meta-Analysis of Randomized Trials. Cardiol. Ther. 2019, 8, 365–372. [Google Scholar] [CrossRef] [Scilit]
  82. Li, L.; Yamani, N.; Al-Naimat, S.; Khurshid, A.; Usman, M.S. Role of losartan in prevention of aortic dilatation in Marfan syndrome: A systematic review and meta-analysis. Eur. J. Prev. Cardiol. 2019. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  83. Forteza, A.; Evangelista, A.; Sánchez, V.; Teixidó-Turà, G.; Sanz, P.; Gutiérrez, L.; Gracia, T.; Centeno, J.; Rodríguez-Palomares, J.; Rufilanchas, J.J.; et al. Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: A randomized clinical trial. Eur. Heart J. 2016, 37, 978–985. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  84. Teixido-Tura, G.; Forteza, A.; Rodríguez-Palomares, J.; González Mirelis, J.; Gutiérrez, L.; Sánchez, V.; Ibáñez, B.; García-Dorado, D.; Evangelista, A. Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome. J. Am. Coll. Cardiol. 2018, 72, 1613–1618. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  85. Whelton, P.K.; Carey, R.M.; Aronow, W.S.; Casey, D.E.; Collins, K.J.; Dennison Himmelfarb, C.; DePalma, S.M.; Gidding, S.; Jamerson, K.A.; Jones, D.W.; et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll Cardiol. 2018, 71, e127–e248. [Google Scholar] [CrossRef] [Scilit]
  86. Bartter, T.; Irwin, R.S.; Nash, G. Aneurysms of the pulmonary arteries. Chest 1988, 94, 1065–1075. [Google Scholar] [CrossRef] [Scilit]
  87. Lammers, S.R.; Kao, P.H.; Qi, H.J.; Hunter, K.; Lanning, C.; Albietz, J.; Hofmeister, S.; Mecham, R.; Stenmark, K.R.; Shandas, R. Changes in the structure-function relationship of elastin and its impact on the proximal pulmonary arterial mechanics of hypertensive calves. Am. J. Physiol. Heart Circ. Physiol. 2008, 295, H1451–H1459. [Google Scholar] [CrossRef] [Scilit]
  88. Pape, L.A.; Tsai, T.T.; Isselbacher, E.M.; Oh, J.K.; O’gara, P.T.; Evangelista, A.; Fattori, R.; Meinhardt, G.; Trimarchi, S.; Bossone, E.; et al. Aortic diameter >or = 5.5 cm is not a good predictor of type A aortic dissection: Observations from the International Registry of Acute Aortic Dissection (IRAD). Circulation 2007, 116, 1120–1127. [Google Scholar] [CrossRef] [Scilit]
  89. Minai, O.A.; Yared, J.P.; Kaw, R.; Subramaniam, K.; Hill, N.S. Perioperative risk and management in patients with pulmonary hypertension. Chest 2013, 144, 329–340. [Google Scholar] [CrossRef] [Scilit]
  90. Delcroix, M.; Naeije, R. Optimising the management of pulmonary arterial hypertension patients: Emergency treatments. Eur. Respir. Rev. 2010, 19, 204–211. [Google Scholar] [CrossRef] [Scilit]
  91. Quezada Loaiza, C.A.; Velázquez Martín, M.T.; Jiménez López-Guarch, C.; Ruiz Cano, M.J.; Navas Tejedor, P.; Carreira, P.E.; Flox Camacho, Á.; de Pablo Gafas, A.; Delgado Jiménez, J.F.; Gómez Sánchez, M.; et al. Trends in Pulmonary Hypertension Over a Period of 30 Years: Experience From a Single Referral Centre. Rev. Esp. Cardiol. (Engl Ed.) 2017, 70, 915–923. [Google Scholar] [CrossRef] [Scilit]
  92. Metras, D.; Ouattara, K.; Quezzin-Coulibaly, A. Aneurysm of the pulmonary artery with cystic medial necrosis and massive pulmonary valvular insufficiency. Report of two successful surgical cases. Eur. J. Cardiothorac Surg. 1987, 1, 119–124. [Google Scholar] [CrossRef] [Scilit]
  93. Galiè, N.; Humbert, M.; Vachiery, J.L.; Gibbs, S.; Lang, I.; Torbicki, A.; Simonneau, G.; Peacock, A.; Vonk Noordegraaf, A.; Beghetti, M.; et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016, 37, 67–119. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  94. Petsophonsakul, P.; Furmanik, M.; Forsythe, R.; Dweck, M.; Schurink, G.W.; Natour, E.; Reutelingsperger, C.; Jacobs, M.; Mees, B.; Schurgers, L. Role of Vascular Smooth Muscle Cell Phenotypic Switching and Calcification in Aortic Aneurysm Formation. Arterioscler. Thromb. Vasc. Biol. 2019, 39, 1351–1368. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  95. Michel, J.B.; Jondeau, G.; Milewicz, D.M. From genetics to response to injury: Vascular smooth muscle cells in aneurysms and dissections of the ascending aorta. Cardiovasc. Res. 2018, 114, 578–589. [Google Scholar] [CrossRef] [Scilit]

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.